Literature DB >> 23430831

Successful screening for Gaucher disease in a high-prevalence population in tabuleiro do Norte (northeastern Brazil): a cross-sectional study.

Rigoberto Gadelha Chaves1, Janice Carneiro Coelho, Kristiane Michelin-Tirelli, Tibelle Freitas Maurício, Edineide de Freitas Maia Chaves, Paulo César de Almeida, Carlos Rômulo Filgueira Maurício, Geraldo Barroso Cavalcanti.   

Abstract

BACKGROUND: Gaucher disease (GD) is a hereditary lysosomal storage disorder characterized by the accumulation of glucosylceramide, mainly in the cells of the reticuloendothelial system, due to a deficiency of the enzyme acid β-glucosidase (GBA). Diagnosis is usually based on measurement of GBA activity in peripheral leukocytes. The purpose of this study was to evaluate the ability of screening for GBA and chitotriosidase activity using dried blood spots on filter paper (DBS-FP) to identify individuals at high risk for GD in high-risk populations such as that of Tabuleiro do Norte, a small town in Northeastern Brazil.
METHODS: Between 1 June 2007 and 31 May 2008, 740 consented residents and descendants of traditional families from Tabuleiro do Norte were submitted to screening with DBS-FP. Subjects with GBA activity < 2.19 nmol/h/mL were referred to the analysis of GBA and chitotriosidase activity in peripheral leukocytes and in plasma, respectively. Subjects at highest risk for GD (GBA activity in peripheral leukocytes < 5.6 nmol/h/mg protein) were referred to molecular analysis to confirm diagnosis.
RESULTS: Screening with DBS-FP identified 135 subjects (18.2%) with GBA activity < 2.19 nmol/h/mL, 131 of whom remained in the study. In ten of these (7.6%), GBA activity in leukocytes was 2.6-5.5 nmol/h/mg protein. Subsequent molecular analysis confirmed six cases of heterozygosity and four normals for GD.
CONCLUSION: DBS-FP assay was shown to be an effective initial GD-screening strategy for high-prevalence populations in developing regions. Diagnosis could not be established from GBA activity in leukocytes alone, but required confirmation with molecular analysis.

Entities:  

Year:  2011        PMID: 23430831      PMCID: PMC3509821          DOI: 10.1007/8904_2011_19

Source DB:  PubMed          Journal:  JIMD Rep        ISSN: 2192-8304


  30 in total

1.  Direct multiplex assay of lysosomal enzymes in dried blood spots for newborn screening.

Authors:  Yijun Li; C Ronald Scott; Nestor A Chamoles; Ahmad Ghavami; B Mario Pinto; Frantisek Turecek; Michael H Gelb
Journal:  Clin Chem       Date:  2004-08-03       Impact factor: 8.327

2.  Misuse of marrow examination in the diagnosis of Gaucher disease.

Authors:  E Beutler; A Saven
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

3.  Multiplex PCR amplification from the CFTR gene using DNA prepared from buccal brushes/swabs.

Authors:  B Richards; J Skoletsky; A P Shuber; R Balfour; R C Stern; H L Dorkin; R B Parad; D Witt; K W Klinger
Journal:  Hum Mol Genet       Date:  1993-02       Impact factor: 6.150

4.  Differentiation of beta-glucocerebrosidase from beta-glucosidase in human tissues using sodium taurocholate.

Authors:  S P Peters; P Coyle; R H Glew
Journal:  Arch Biochem Biophys       Date:  1976-08       Impact factor: 4.013

5.  Demonstration of a deficiency of glucocerebroside-cleaving enzyme in Gaucher's disease.

Authors:  R O Brady; J N Kanfer; R M Bradley; D Shapiro
Journal:  J Clin Invest       Date:  1966-07       Impact factor: 14.808

6.  Correlation of surrogate markers of Gaucher disease. Implications for long-term follow up of enzyme replacement therapy.

Authors:  Mario A Cabrera-Salazar; Erin O'Rourke; Nadene Henderson; Howard Wessel; John A Barranger
Journal:  Clin Chim Acta       Date:  2004-06       Impact factor: 3.786

7.  Newborn screening for lysosomal storage disorders: clinical evaluation of a two-tier strategy.

Authors:  Peter J Meikle; Enzo Ranieri; Henrik Simonsen; Tina Rozaklis; Steve L Ramsay; Phillip D Whitfield; Maria Fuller; Ernst Christensen; Flemming Skovby; John J Hopwood
Journal:  Pediatrics       Date:  2004-10       Impact factor: 7.124

8.  Genetic diagnosis of Gaucher's disease.

Authors:  P K Mistry; S J Smith; M Ali; C S Hatton; N McIntyre; T M Cox
Journal:  Lancet       Date:  1992-04-11       Impact factor: 79.321

9.  Imiglucerase (Cerezyme) improves quality of life in patients with skeletal manifestations of Gaucher disease.

Authors:  N Weinreb; J Barranger; S Packman; A Prakash-Cheng; B Rosenbloom; K Sims; J Angell; A Skrinar; G M Pastores
Journal:  Clin Genet       Date:  2007-06       Impact factor: 4.438

Review 10.  [Therapeutic objectives in Gaucher disease].

Authors:  P Mistry; D P Germain
Journal:  Rev Med Interne       Date:  2007-10       Impact factor: 0.728

View more
  1 in total

1.  Clusters of genetic diseases in Brazil.

Authors:  Gabriela Costa Cardoso; Marcelo Zagonel de Oliveira; Vanessa Rodrigues Paixão-Côrtes; Eduardo Enrique Castilla; Lavínia Schuler-Faccini
Journal:  J Community Genet       Date:  2018-06-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.